Bellus Data Flop Catches Market By Surprise
Insights - Bellus announced Phase 2 data this morning and it was a major flop. The stock is down 75%. Bellus did not hit statistical significance in any of … Continue Reading
PremiumSearch Results for bellus
Merck’s Phase 3 Chronic Cough Data Further Validates Bellus’ P2X3 Approach
Insights - Bellus (BLU) is up over 10% this morning on news that Merck’s Phase 3 candidate gefapixant met efficacy endpoints in chronic cough (read here). Merck … Continue Reading
Read nowShionogi Taste Data Validates Selective P2X3 & Bellus
Insights - More data from Shionogi, Bellus’ competitor, was presented at European Respiratory Society (ERS) this weekend. Shionogi presented an abstract for their selective P2X3 antagonist, S-600918, and showed … Continue Reading
Read now
Bellus Uplists & Fennec’s Plan B for Self-Commercialization
Insights - Last week Bellus uplisted to the Nasdaq, trading under ticker BLU. To complete the uplisting, Bellus announced a 3.6:1 consolidation of common shares and a … Continue Reading
Read nowKey Takeaways From Bellus’ Chronic Cough KOL Call
Insights - Bellus hosted their Chronic Cough KOL meeting this morning. It was paneled by: Jacky Smith: lead investigator of Bellus Phase 2 trials Denis Garceau: Bellus VP of … Continue Reading
Read nowMerck’s Plan of a P2X3 Pipeline Lifts Bellus
Insights - Last week, Bellus (BLUSF) rallied from $1.50 range to over $2.00, touching a high of $2.31. This all happened on heavy volume. Remember, we first … Continue Reading
Read nowThe Street is Finally Starting to Pick Up on Bellus’ Story
Insights - It seems the market is starting to realize Bellus’ potential as the company touched a 52 week high today on the Canadian listing when it … Continue Reading
Read now